Literature DB >> 2262356

Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer.

F Sanchíz1, A Millá, J Torner, F Bonet, N Artola, L Carreño, L M Moya, D Riera, S Ripol, L Cirera.   

Abstract

From January 1978 to January 1988, 859 patients with T3-T4, NO-3, MO were randomly allocated to receive either: Group A--60Co 60, 60 Gy in 30 fractions; Group B--60Co, 70.4 Gy in 64 fractions; Group C--60Co, 60 Gy in 30 fractions plus chemotherapy (5 Fu, 250 mg/m2/IV every 2 days). Chemotherapy and radiotherapy were combined simultaneously. The average age was 56 years; the male/female ratio was 802/57. Median performance status (ECOG scale) was 1 (range 0-2). The TNM distribution as UICC criteria was T3 529 patients; T4 330 patients; No 217 patients; N1 52 patients; N2 319 patients; and N3 271 patients. The primary sites were nasopharynx 92, oral cavity 252, hypopharynx 119, larynx 310, and others (sinuses and unknown primary)86. Complete response was achieved in 188/277 patients in Group A (67.8%), 254/282 patients in Group B (90%), and 289/300 in Group C (96.3%). All patients were followed and statistical analysis shows a significant improvement in median duration of response, as well as survival for Groups B and C compared with Group A. No significant differences were seen between Group B and C. The acute toxicity was mucositis, skin toxicity, bone marrow depression. A mean temporary weight loss of 4.9 Kg was observed with a range of 2.3-10.5 Kg.

Entities:  

Mesh:

Year:  1990        PMID: 2262356     DOI: 10.1016/0360-3016(90)90342-h

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  14 in total

Review 1.  Altered fractionation in the treatment of head and neck cancer.

Authors:  K S Hu; L B Harrison
Journal:  Curr Oncol Rep       Date:  1999       Impact factor: 5.075

Review 2.  Concurrent chemoradiotherapy in head and neck cancer.

Authors:  S G Urba
Journal:  Curr Oncol Rep       Date:  1999       Impact factor: 5.075

3.  Altered and conventional fractionated radiotherapy in locoregional control and survival of patients with squamous cell carcinoma of the larynx, oropharynx, and hypopharynx.

Authors:  Valentina Krstevska; Simonida Crvenkova
Journal:  Croat Med J       Date:  2006-02       Impact factor: 1.351

4.  [A phase-I/II study on the local hyperthermia of cervical N2/N3 lymph node metastases].

Authors:  H Stahl; P Wust; R Graf; J Löffel; J Bier; H Riess; V Jahnke; R Felix
Journal:  Strahlenther Onkol       Date:  1997-04       Impact factor: 3.621

5.  Carboplatin and tegafur-uracil concomitant with standard radiotherapy in the management of locally advanced head and neck cancer.

Authors:  Angel Segura Huerta; Roberto Díaz-Beveridge; José A Pérez-Fidalgo; Verónica Calderero Aragón; Miguel Pastor Borgoñón; Jorge Aparicio Urtasun; Joaquín Montalar Salcedo
Journal:  Clin Transl Oncol       Date:  2005 Jan-Feb       Impact factor: 3.405

6.  Combined modality treatment with full-dose chemotherapy and concomitant boost radiotherapy for advanced head and neck carcinoma.

Authors:  Jürg Kutter; Mahmut Ozsahin; Philippe Monnier; Roger Stupp
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-03-05       Impact factor: 2.503

Review 7.  Hyperfractionated or accelerated radiotherapy for head and neck cancer.

Authors:  Bertrand Baujat; Jean Bourhis; Pierre Blanchard; Jens Overgaard; Kian K Ang; Michelle Saunders; Aurélie Le Maître; Jacques Bernier; Jean Claude Horiot; Emilie Maillard; Thomas F Pajak; Michael G Poulsen; Abderrahmane Bourredjem; Brian O'Sullivan; Werner Dobrowsky; Hliniak Andrzej; Krzystof Skladowski; John H Hay; Luiz Hj Pinto; Karen K Fu; Carlo Fallai; Richard Sylvester; Jean Pierre Pignon
Journal:  Cochrane Database Syst Rev       Date:  2010-12-08

8.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group.

Authors:  Benjamin Lacas; Alexandra Carmel; Cécile Landais; Stuart J Wong; Lisa Licitra; Jeffrey S Tobias; Barbara Burtness; Maria Grazia Ghi; Ezra E W Cohen; Cai Grau; Gregory Wolf; Ricardo Hitt; Renzo Corvò; Volker Budach; Shaleen Kumar; Sarbani Ghosh Laskar; Jean-Jacques Mazeron; Lai-Ping Zhong; Werner Dobrowsky; Pirus Ghadjar; Carlo Fallai; Branko Zakotnik; Atul Sharma; René-Jean Bensadoun; Maria Grazia Ruo Redda; Séverine Racadot; George Fountzilas; David Brizel; Paolo Rovea; Athanassios Argiris; Zoltán Takácsi Nagy; Ju-Whei Lee; Catherine Fortpied; Jonathan Harris; Jean Bourhis; Anne Aupérin; Pierre Blanchard; Jean-Pierre Pignon
Journal:  Radiother Oncol       Date:  2021-01-27       Impact factor: 6.280

9.  A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck.

Authors:  W Budach; T Hehr; V Budach; C Belka; K Dietz
Journal:  BMC Cancer       Date:  2006-01-31       Impact factor: 4.430

10.  An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer.

Authors:  A J Munro
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.